Bicycle Therapeutics Plc ADR Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.34 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $3.68Price as of 30 Sep 2026 Data confidence Sign in to view data confidence Market Cap $257.6M Enterprise Value −$244M Shares Outstanding 69.8M diluted Next Earnings Date5 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Bicycle Therapeutics is transitioning through a critical strategic pivot, shifting its primary focus from its lead Nectin-4 program (zelenectide pevedotin) to its highly promising next-generation conjugates, specifically nuzefatide pevedotin (targeting EphA2) and its emerging radiopharmaceutical pipeline. By implementing a 30% workforce reduction and narrowing its clinical focus, the company has successfully extended its cash runway into 2030. This robust balance sheet, combined with a highly differentiated synthetic bicyclic peptide platform that offers the targeting precision of antibodies with the rapid clearance of small molecules, positions the company as an attractive, de-risked play in the oncology space. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$5.00 Mean target$13.57 High · most bullish analyst$36.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The strategic pivot fails to yield positive clinical results for nuzefatide pevedotin, or safety concerns emerge in the Phase 2 PDAC trial. The company is unable to find partners for its deprioritized assets (zelenectide pevedotin and BT7480), leading to complete write-downs. Operational cash burn remains higher than projected despite the workforce reduction, shortening the cash runway. Base CaseCentral scenario The company successfully executes its restructuring, achieving a 50% reduction in annual operating expenses. Nuzefatide pevedotin demonstrates strong efficacy and a superior safety profile (particularly regarding peripheral neuropathy and skin toxicities compared to traditional ADCs) in its Phase 2 PDAC trial. The radiopharmaceutical pipeline advances with key imaging readouts, and the company secures a development partner for zelenectide pevedotin or BT7480. Bull CaseUpside scenario Successful clinical development and commercialization of nuzefatide pevedotin (EphA2) and the radiopharmaceutical pipeline (BT1702), supported by a secure Lead-212 supply chain and a cash runway extending into 2030. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |